Is corticotropin the same as cortisol?

No. Corticotropin (ACTH) is the hormone that *stimulates* the adrenal glands to produce cortisol. Cortisol is the end product. Corticotropin is a 39-amino-acid peptide produced by the pituitary; cortisol is a steroid hormone made by the adrenal cortex in response to ACTH signaling.

Why is corticotropin approved by the FDA but not the EMA?

Regulatory agencies assess risk-benefit differently based on local disease burden and treatment alternatives. The FDA approved corticotropin for infantile spasms and other indications where clinical benefit is clear. European regulators may prioritize alternative treatments or require different evidence standards, leading to non-approval decisions.

How many clinical trials have tested corticotropin?

Over 185 clinical trials have investigated corticotropin, spanning diagnostic applications, infantile spasms, multiple sclerosis exacerbations, adrenal insufficiency, and emerging indications. This extensive research demonstrates corticotropin's established clinical utility and ongoing scientific interest.

What is the ACTH stimulation test?

A diagnostic test where synthetic corticotropin is injected and serum cortisol is measured 30–60 minutes later. A normal cortisol rise indicates healthy adrenal function; a blunted response suggests primary adrenal insufficiency (Addison's disease). It remains the gold standard diagnostic test for this condition.

Is corticotropin used long-term?

Yes, for replacement therapy in adrenal insufficiency. However, most acute applications (infantile spasms, MS exacerbations) involve short-term courses. Long-term use requires monitoring for steroid-related side effects like hypertension and metabolic changes, similar to any glucocorticoid regimen.

Corticotropin Research: Clinical Studies & FDA Approval

Corticotropin is an FDA-approved peptide hormone that stimulates cortisol production in the adrenal glands. Also known as adrenocorticotropic hormone (ACTH), corticotropin has been the subject of 185 clinical trials exploring its therapeutic applications. Originally isolated in the 1930s, it remains a cornerstone of endocrine research and clinical practice. The peptide works by binding to melanocortin-2 receptors on adrenocortical cells, triggering a cascade that drives glucocorticoid synthesis. Modern corticotropin research spans rare genetic disorders, autoimmune conditions, and neuroinflammatory diseases, with robust FDA approval backing its clinical use.

Understanding Corticotropin: The Core Hormone

Corticotropin, also called ACTH (adrenocorticotropic hormone), is a 39-amino-acid peptide produced by the anterior pituitary gland. Research dating back decades shows that this hormone is the primary signal the body uses to regulate cortisol release from the adrenal cortex. Unlike many investigational peptides, corticotropin carries full FDA approval and has established clinical utility—a status earned through extensive research and decades of clinical practice.

The hormone's mechanism is elegant: corticotropin circulates through the bloodstream and binds to melanocortin-2 receptors on adrenocortical cells. This binding initiates intracellular signaling that increases cholesterol uptake, enhances enzyme activity, and ultimately drives cortisol and adrenal androgens into circulation. This regulatory axis—the hypothalamic-pituitary-adrenal (HPA) axis—is one of the body's most critical stress-response systems.

The Research Landscape: 185 Trials and Counting

Corticotropin has been the focus of 185 registered clinical trials, representing one of the most extensively studied peptide hormones. These trials span multiple disease areas, patient populations, and therapeutic applications. The sheer volume of research underscores both the historical importance of corticotropin in medicine and its continued relevance to modern clinical investigation.

Early research established corticotropin's role in diagnostic testing—the ACTH stimulation test remains a gold standard for assessing adrenal function. Classical studies from the endocrinology literature demonstrated that synthetic corticotropin injection reliably triggers cortisol secretion, making it invaluable for distinguishing primary adrenal insufficiency from secondary (pituitary-driven) insufficiency.

Approved Clinical Uses and FDA Status

Corticotropin gained FDA approval for multiple therapeutic indications based on solid clinical evidence. In the United States, it is approved for:

Adrenocortical insufficiency (primary and secondary)—replacement therapy when the adrenal glands or pituitary fail to produce adequate hormone
Diagnostic testing—the ACTH stimulation test for adrenal assessment
Infantile spasms (West syndrome)—a rare, severe seizure disorder in infants where corticotropin has shown remarkable efficacy
Multiple sclerosis exacerbations—short-term immunomodulatory use during acute disease flares

The European Medicines Agency (EMA) has not authorised corticotropin, and Health Canada has not approved it, reflecting regional differences in regulatory assessment and clinical need.

Research Evidence: Infantile Spasms and Neuroinflammation

One of the most compelling areas of corticotropin research is infantile spasms, also called West syndrome. Clinical trials have documented response rates of 60–90% in infants treated with ACTH, with seizure clusters often resolving within days of starting therapy. The mechanism is thought to involve ACTH-mediated suppression of inflammatory cytokines and modulation of GABAergic tone in the developing brain.

For multiple sclerosis (MS) exacerbations, corticotropin research has produced interesting comparisons with standard corticosteroids. Studies suggest comparable efficacy to intravenous methylprednisolone for acute relapses, with some researchers noting a potentially broader immunoregulatory profile. The peptide appears to activate both anti-inflammatory and immunosuppressive pathways, distinct from the narrow corticosteroid receptor mechanism.

This research connects to broader investigation of peptide therapeutics. Investigators exploring compounds like Abaloparatide in bone disorders or Bacitracin in wound healing have similarly leveraged peptide-based signaling to achieve therapeutic effects that small molecules struggle to match.

Diagnostic Excellence: The ACTH Stimulation Test

Beyond direct therapeutic use, corticotropin's role in diagnostic research is foundational. The standard ACTH stimulation test—administering synthetic corticotropin and measuring the cortisol response—remains the diagnostic gold standard for primary adrenal insufficiency. A normal cortisol response rules out Addison's disease; a blunted response confirms adrenal failure.

Research has refined the protocol over decades. Lower-dose stimulation tests, high-dose variants, and combined pituitary hormone testing have all emerged from clinical investigation. This diagnostic precision exemplifies how corticotropin research translates directly into clinical practice, benefiting countless patients with endocrine disorders.

The HPA Axis and Systemic Inflammation

Contemporary corticotropin research increasingly focuses on the broader neuroimmune implications of HPA axis dysregulation. Stress, infection, and autoimmune disease all trigger aberrant corticotropin signaling. Understanding how synthetic corticotropin modulates this axis has led to novel applications in conditions like polymyalgia rheumatica and other inflammatory disorders.

Likewise, researchers investigating other peptide hormones—such as Alexamorelin, a growth hormone secretagogue under investigation—are exploring how peptide-mediated endocrine signaling can reshape immune tolerance. Corticotropin's established mechanisms provide a template for understanding how peptide-receptor interactions influence systemic inflammation.

Safety Profile and Long-Term Research

Decades of clinical corticotropin research have established a well-characterized safety profile. Short-term use for acute indications (MS exacerbations, infantile spasms) is generally well-tolerated. Longer-term replacement therapy in adrenal insufficiency requires careful monitoring, much like any chronic corticosteroid regimen, but the peptide's physiologic mode of action (stimulating endogenous hormone production rather than replacing a synthetic steroid) offers theoretical advantages.

Adverse event surveillance from large clinical cohorts documents common side effects including hypertension, hypokalemia, hyperglycemia, and mood changes—all consistent with elevated cortisol levels—but serious or unexpected toxicities remain rare. This safety data underpins corticotropin's continued FDA approval and clinical use.

Future Directions in Corticotropin Research

The 185 ongoing and completed trials reflect evolving interest in corticotropin for emerging indications. Researchers are investigating:

Systemic inflammation and sepsis—whether early ACTH administration mitigates organ dysfunction
Autoimmune encephalitis—novel neuropsychiatric applications beyond infantile spasms
Rare genetic disorders of steroidogenesis—expanding replacement therapy options

Meanwhile, peptide research broadly—including work on compounds like ACE-031 for muscle wasting and Afamelanotide for photoprotection—continues to demonstrate that peptide hormones and analogues can achieve therapeutic effects with mechanistic specificity that older small-molecule drugs cannot match.

Regulatory Context and Access

Corticotropin's FDA approval ensures pharmaceutical-grade manufacturing, purity, and potency. This differs sharply from research compounds sourced outside regulated channels. For patients and clinicians, FDA approval means standardized dosing, clear labeling, and post-market safety monitoring.

The absence of EMA authorisation reflects European regulatory conservatism; alternative treatments for most corticotropin indications are available in Europe (e.g., conventional corticosteroids for MS exacerbations), reducing the urgency for EMA review.

Why Corticotropin Research Matters

Corticotropin exemplifies how decades of rigorous research can transform a hormone from a laboratory curiosity into a precision therapeutic. Its 185 clinical trials represent investment from academic researchers, pharmaceutical manufacturers, and regulatory agencies—all working to expand our understanding of HPA axis physiology and endocrine pharmacology. Whether for diagnosing adrenal disease, treating infantile spasms, or managing MS exacerbations, corticotropin research continues to shape clinical practice and inform the development of next-generation peptide therapeutics.

Corticotropin Research: What 185+ Clinical Trials Reveal